Investors

Best-in-Class Treatment for DDD

Notogen presents a unique opportunity to invest in the expansive spine and orthopedic medicine therapeutic technology space. A profound void exists in the continuum of care related to non-surgical intervention for back pain. NTG-101 is positioned to address this void with a simple, cost-effective solution. Notogen has secured investment to achieve its near-term goals.

Events & Presentations

Jun 2021

Virtual
BIO Digital 2021

Mar 2021

Virtual
Cooley Capital Call Life Sciences

Feb 2021

Virtual
2021 OBIO Investment Summit

Oct 2020

Virtual
BIO Investor Forum

Oct 2020

Virtual
Animal Health Investment USA – Innovation Showcase

Oct 2020

Virtual
North American Spine Society (NASS) 35th Annual Meeting

Best Paper Award: “The effects of a single injection of NTG-101 upon neurotrophin expression in a canine model of degenerative disc disease”
Podium Presentation: “Study comparing NTG-101, a growth factor-based therapy with mesenchymal stem cell (MSC) based treatment of degenerative disc disease (DDD) in pre-clinical rodent model”

Jun 2020

Virtual
BIO International Convention

Jun 2020

Philadelphia, PA
Redefining Early Stage Investments Conference – Innovation Challenge Finalist

Feb 2020

Niagara, ON
2020 Niagara Investment Summit

Oct 2018

Chicago, IL
2018 Biologic: Interventions for Spinal Pathologies: Stem Cells, Growth Factors & Novel Therapeutics